References
1
Cole C.
Foster AJ.
Freeman S.
Jaffar M.
Murray P.
Stratford IJ.
Anti-Cancer Drug Des.
1999,
14:
383 , and references cited therein
2
Balzarini J.
Esteban-Gamboa A.
Esnouf R.
Liekens S.
Neyts J.
De Clercq E.
Camarasa MJ.
Pérez-Pérez MJ.
FEBS Lett.
1998,
438:
91
3
Hutzenlaub W.
Pfleiderer W.
Liebigs Ann. Chem.
1979,
1847
4
Müller CE.
Geis U.
Hipp J.
Schobert U.
Frobenius W.
Pawloski M.
Suzuki F.
Sandoval-Ramírez J.
J. Med. Chem.
1997,
40:
4396
5
Jacobson KA. In
Comprehensive Medicinal Chemistry
Vol. 3:
Emmet JC.
Pergamon Press;
Oxford:
1990.
p.625
6
Rybar A.
Hesek D.
Szemes F.
Alföldi J.
Tegza M.
Collect. Czech. Chem. Commun.
1990,
55:
2257
7
Esteban-Gamboa A.
Balzarini J.
Esnouf R.
De Clercq E.
Camarasa MJ.
Pérez-Pérez MJ.
J. Med. Chem.
2000,
43:
971
8 Selected data of 3: Mp (CH2Cl2-MeOH): 298-299 °C. MS (EI): m/z = 292 [M+]. 1H NMR (DMSO-d6): δ 5.22 (s, 2 H, CH2Ph), 7.10-7.50 (m, 6 H, H-7, Ph), 7.66 (m, J = 7.1, 1.2 Hz, H-8), 7.75 (d, J = 9.1 Hz, 1 H, H-9), 8.94 (d, J = 6.6 Hz, H-6), 11.35 (br s, 1 H, NH). 13C NMR (DMSO-d6): δ 44.92 (CH2Ph), 101.95 (C-4a), 114.51 (C-7), 116.08 (C-9), 127.11, 127.20, 128.32, 136.71 (C-6, Ph), 130.34 (C-8), 147.08 (C-9a), 150.85 (C-10a), 151.60 (C-2), 154.53 (C-4). Anal. Calcd for C16H12N4O2: C, 65.75; H, 4.14; N, 19.17; found: C, 65.47; H, 4.50; N, 19.35.
9
10
Gatta F.
Del Giudice MR.
Borioni A.
Mustazza C.
J. Heterocycl. Chem.
1994,
31:
81
11
Priego EM.
Camarasa MJ.
Pérez-Pérez MJ.
Synthesis
2001,
478
12 Selected data of 5: MS (ES, positive mode): m/z = 360, [M + Na+], showing the Br isotopic pattern. 1H NMR (CDCl3): δ 0.97 (t, 3 H, CH
3
CH2), 1.72 (m, 2 H, CH3CH
2
), 4.00 (m, 2 H, NCH2), 4.97 (br s, 2 H, NH2), 5.28 (s, 2 H, CH2Ph), 7.26-7.43 (m, 5 H, Ph). 13C NMR (CDCl3): δ 11.32 (CH3CH2), 21.11 (CH3
CH2), 44.40 (NCH2), 47.78 (CH2Ph), 73.25 (C-5), 150.40, 150.93 (C-2, C-6), 158.52 (C-4).
13 Selected data of 6: Mp (CH2Cl2-MeOH): 163-165 °C. MS (EI): m/z = 334 [M+]. 1H NMR (CDCl3): δ 0.95 (t, J = 7.5 Hz, 3 H, CH3), 1.69 (m, J = 7.5 Hz, 2 H, CH
2
CH3), 4.01 (pt, J = 7.3 Hz, 2 H, NCH2), 5.37 (s, 2 H, CH2Ph), 7.06 (pt, J = 6.1 Hz, H-7), 7.25-7.52 (m, 5 H, Ph), 7.52 (pt, J = 7.0 Hz, H-8), 7.65 (d, J = 7.0 Hz, 1 H, H-9), 9.04 (d, J = 6.7 Hz, 1 H, H-6). 13C NMR (CDCl3): δ 11.32 (CH3CH2), 21.38 (CH3
CH2), 42.83 (NCH2), 46.67 (CH2Ph), 101.90 (C-4a), 113.90 (C-7), 116.41 (C-9), 127.48 (C-6), 129.87 (C-8), 147.63 (C-9a), 150.69 (C-10a), 151.39 (C-2), 155.01 (C-4). Anal. Calcd for C19H18N4O2: C, 68.25; H, 5.43; N, 19.76; found: C, 68.19; H, 5.12; N, 19.40.
14 Selected data of 7: MS (ES, positive mode): m/z = 416 [M + 1]+, showing the isotopic 2 Br pattern. 1H NMR (CDCl3): δ 0.97 (t, 3 H, CH
3
CH2), 1.67 (m, 2 H, CH3CH
2
), 3.90 (m, 2 H, NCH2), 5.31 (s, 2 H, CH2Ph), 7.28-7.49 (m, 5 H, Ph), 9.59 (br s, 1 H, NH). 13C NMR (CDCl3): δ 10.94 (CH3CH2), 20.68 (CH3
CH2), 45.38 (NCH2), 48.40 (CH2Ph), 50.58 (C-5), 149.14 (C-2), 156.52 (C-6), 161.05 (C-4).
15 The dibromination of 6-amino-1-methyluracil has been proposed in the synthesis of pyrimidin-5-yl sulphides and disulphides: Barker GR.
Luthy NG.
J. Chem. Soc.
1956,
917
16
Taylor EC.
Paudler WW.
Cain CK.
J. Org. Chem.
1955,
20:
264
17a
Peichl E.
Kappe T.
Arch. Pharm.
1984,
317:
946
17b
Kappe T.
Khorchid-Zadeh R.
Steininger H.
Z. Naturforsch.
1975,
30b:
773
18
General Experimental Procedure: Synthesis of 3, 9 and 10. N-Bromosuccinimide (NBS) (445 mg, 2.5 mmol) was added into a suspension of 6-amino-1-benzyluracil 1 (217 mg, 1.0 mmol) in dry CH3CN (8 mL) and the mixture was heated at 80 ºC for 1 h till all starting material was transformed into the 5,5-dibromoderivative 8. After cooling to r.t., the corresponding pyridine (5-10 mmol) was added, and the resulting mixture was heated at 80 °C for 6 h. The resulting precipitate, that contains the target compound, was collected by filtration and washed with ethyl ether.
19
Scriven EFV. In
Comprehensive Heterocyclic Chemistry
Vol. 2:
Katritzky AR.
Rees CW.
Pergamon;
Oxford:
1984.
p.166
